IDH-mutant Low-Grade Glioma Active Surveillance, MSK, Clin Cancer Res 2023

Overview

Retrospective MSKCC cohort of 128 consecutive adult patients with WHO 2016 Grade 2 IDH-mutant astrocytoma or oligodendroglioma evaluated 1997–2019, all observed without upfront chemoradiation after biopsy/resection. Built to characterize tumor volume growth rates (TVGR) during active surveillance and correlate with molecular grade PMID:37910594.

Composition

  • 128 adult patients with WHO 2016 Grade 2 IDH-mutant glioma; 69 (53.9%) 1p19q codeleted oligodendrogliomas and 59 (46.1%) 1p19q intact astrocytomas PMID:37910594.
  • Cancer types: DIFG, ASTR, ODG.
  • Median follow-up 6.3 years (range 0.5–23.1); median 8 MRI scans per patient (range 2–28) PMID:37910594.
  • MSK-IMPACT targeted sequencing on 73/128 patients with tissue available PMID:37910594.
  • Manual 3D volumetric T2/FLAIR segmentation with VASARI feature annotation.

Assays / panels (linked)

Papers using this cohort

  • PMID:37910594 — Bhatia et al., Tumor Volume Growth Rates and Doubling Times during Active Surveillance of IDH-mutant Low-Grade Glioma, Clin Cancer Res 2024.

Notable findings derived from this cohort

  • Continuous TVGR = 10.46% per 6 months (95% CI 9.11–11.83), doubling time 3.5 years PMID:37910594.
  • CDKN2A/B homozygous deletion (“molecular grade-high”) drove ~2× faster TVGR (19.17% vs 9.54% per 6 months, P<0.0001) PMID:37910594.
  • Joint longitudinal-survival model: each ln(tumor volume) unit increase → HR=3.83 for overall survival PMID:37910594.
  • Mutation landscape: codeleted tumors showed TERT promoter 100%, CIC 42%, FUBP1 24%; intact tumors TP53 94%, ATRX 77% PMID:37910594.

Sources

  • cBioPortal study difg_msk_2023; data also released on Synapse syn52658621 PMID:37910594.

This page was processed by entity-page-writer on 2026-04-08.